NEWS RELEASE

Teijin to Commence Manufacture and Sale in Japan ofAbaloparatide Acetate as Treatment for Osteoporosis
Tokyo, Japan, March 23, 2021 --- Teijin Pharma Limited, the core company of the TeijinGroup’s healthcare business, announced today that on March 23 it will commence themanufacture and sale of its OSTABALO® abaloparatide acetate treatment in Japan. The
new solution has been approved for the treatment of osteoporosis and will help promotebone formation in patients with high risk of bone fractures.
Now Teijin Pharma is developing an additional dosage for OSTABALO® in order torespond to Japan’s 14-day prescription limit. The date when Teijin Pharma starts
exclusive sales of OSTABALO® in Japan is undecided.
Product name
General name
Dosage form
Efficacy and effect
Usage and dose

OSTABALO ® Subcutaneous Injection Cart
Abaloparatide acetate
Aqueous injection (cartridge)
Osteoporosis where there is a high risk of bone fractures
For adults, subcutaneous injection of 80μg as an abaloparatide
once a day. Administration limited to 18 months.

Under its current medium-term management plan, the Teijin Group is contributing tosustainability by developing solutions that make allowance for demographic change andaddress increased health consciousness. The launch of new drugs will be a key factor
in the implementation of this plan. The Teijin Group will continue to enhance patients’quality of life by providing new treatment options for diseases with high unmet needs.
The active ingredient in OSTABALO® Subcutaneous Injection Cart is abaloparatideacetate, a polypeptide containing a modification of one part of the 34 amino acidsequences from the N-terminus of human parathyroid hormone-related peptide (PTHrP).
Abaloparatide selectively stimulates parathyroid hormone type 1 receptors involved inbone metabolism, and when administered subcutaneously once a day, promotes boneformation through an increase in osteoblasts; it may also increase bone mass.
The efficacy and safety of OSTABALO® Subcutaneous Injection Cart have been
confirmed in clinical trials in Japan and worldwide involving osteoporosis patients with ahigh risk of bone fractures. In May 2020, Teijin Pharma accordingly applied for approvalin Japan to manufacture and sell OSTABALO® Subcutaneous Injection Cart as a newtreatment option.
In April 2017, Radius Health, Inc. received Food and Drug Administration (FDA) approvalin the United States for Tymlos® (abaloparatide-SC) for the treatment forpostmenopausal women with osteoporosis at high risk for fracture.

Japan is estimated to have about 13 million patients with osteoporosis (*1), many ofwhom are at risk of bone fractures that could greatly reduce their scope for everyday
activity and their quality of life. Osteoporosis is particularly troublesome for those withlow bone density, bone fragility or a high frequency of fractures due to aging. There isstrong demand in Japan for therapeutic drugs capable of increasing bone mass quickly
to help patients avoid debilitating bone fractures.
(*1) Guidelines for Prevention AND Treatment of OSTEOPOROSIS 2015

Teijin Pharma is helping to improve patients’ quality of life through solutions that address
problems with bones and joints; these include its osteoporosis drugs ONEALFA® andBONALON® (*2) and sonic accelerated fracture healing system SAFHS®.
(*2) BONALON® is the registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station,NJ, USA.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions”, Teijin aims to be a company thatsupports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2020.
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp